Pharmacology, in vitro activity, and in vivo efficacy of new antifungal agents

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Invasive fungal infections remain significant clinical challenges and are associated with high morbidity and mortality in immunocompromised patients. Despite the availability of new antifungal agents, response rates against many of these infections remain suboptimal. In addition, many of the clinically available agents have limited oral bioavailability, are associated with adverse effects due to similarities between fungal and mammalian cells, or have significant drug-drug interactions. For these reasons, there is great interest in developing new antifungal drugs, including those with novel mechanisms of action. This article reviews the pharmacology, in vitro activity, and in vivo effectiveness of new antifungal agents, including members of new classes with novel mechanisms of action and at various stages of preclinical and clinical development. These agents include the triazole isavuconazole, the echinocandin aminocandin, the histone deacetylase inhibitor MGCD290, and the sordarin derivative FR290581.

Original languageEnglish (US)
Pages (from-to)77-85
Number of pages9
JournalCurrent Fungal Infection Reports
Issue number2
StatePublished - Jun 2009

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Pharmacology, in vitro activity, and in vivo efficacy of new antifungal agents'. Together they form a unique fingerprint.

Cite this